Vitamin B12: What the Dose on the Label Actually Means

A bottle marked 1,000 micrograms can make vitamin B12 look like an energy product. The adult recommended intake is 2.4 micrograms a day. That gap is not a mistake: B12 absorption changes with dose, and large numbers on a label do not tell you whether you need the product, whether the form is special, or whether tiredness has anything to do with B12.

Vitamin B12 is essential for blood-cell formation, nerve function and DNA synthesis. It is also a nutrient where the sensible next step is often a food check, a medication review or a clinician-led test, rather than choosing the highest-dose bottle. This guide separates what B12 does, who may be at risk of low status, and what a New Zealand supplement label can and cannot tell you.

B12 is cobalamin, not an energy shortcut

Vitamin B12 is a water-soluble vitamin containing cobalt, which is why its related compounds are called cobalamins. In cells, B12 acts as a cofactor for two enzymes. Those reactions support DNA synthesis, red blood cell production and normal nervous-system development and function. Severe deficiency can produce megaloblastic anaemia and neurological symptoms.

That biology is real. It does not turn B12 into a general-purpose stimulant. The NIH Office of Dietary Supplements says B12 supplements do not improve energy, athletic performance or endurance in people who already get enough B12. A person can feel tired for many reasons, including sleep, infection, iron deficiency, thyroid disease, mood, medicines and chronic illness. A supplement aisle cannot sort those causes.

The useful distinction is between correcting a confirmed or likely deficiency and adding more B12 to an already adequate intake. The first may be clinically important. The second should not be sold as a shortcut to energy.

Deficiency is not rare, but estimates vary widely depending on the cutoff and population studied. NIH cites NHANES data suggesting roughly 3.6% of US adults aged 19 and older have B12 deficiency using a strict cutoff, while a looser insufficiency threshold captures around 12.5% of the same group. Australian Prescriber reports a prevalence of 5.2% to 6.3% in Australians over 50, rising to 20% to 30% in some refugee populations from Sudan, Bhutan, Iran, Iraq and Afghanistan, reflecting different dietary patterns and healthcare access before arrival. Those ranges show why a single national number cannot tell an individual reader whether they personally need to worry; it depends on age, diet, medical history and medicines.

The daily target is small

For adults, the recommended dietary allowance used by the US National Academies is 2.4 micrograms a day. The recommendation rises to 2.6 micrograms in pregnancy and 2.8 micrograms while breastfeeding. These figures describe intake targets for healthy people. They are not treatment doses for a diagnosed deficiency or malabsorption condition.

A microgram is one millionth of a gram. This is why a 500 or 1,000 microgram tablet can appear enormous beside the daily target. The body has a limited intrinsic-factor transport system for B12. At small doses it can absorb a larger proportion; at high doses the percentage absorbed falls. The NIH fact sheet gives an estimate of about 2% absorbed from a 500 microgram dose and 1.3% from a 1,000 microgram dose.

That declining percentage helps explain why high-dose oral products exist. It does not make their number a measure of quality. A clinician may choose a high-dose oral product for a specific reason, but the reason matters as much as the amount.

Older adults are a useful example of why the daily target does not change even when risk does. The recommended intake for adults over 50 is still 2.4 micrograms; what changes is where that amount should come from. NIH notes that many older adults have reduced stomach acid and cannot efficiently release the B12 that is naturally bound to protein in meat, fish and dairy. For that reason, people over 50 are generally advised to get most of their B12 from fortified foods or supplements, where the vitamin is already in a free form that does not require the same digestive step. That is a sourcing change, not a dose increase.

Food sources deserve the first look

Vitamin B12 occurs naturally in foods of animal origin. Fish, meat, poultry, eggs, milk and other dairy foods contribute B12. The NIH lists cooked clams, oysters and beef liver among particularly rich sources; salmon, tuna, beef, milk, yoghurt, cheese and eggs also provide B12 in ordinary servings.

Plant foods do not naturally supply reliable B12. Fortified foods are the exception. Breakfast cereals, nutritional yeast and plant-based milks may have B12 added during processing, but the amount and serving size vary. Read the nutrition information rather than assuming a product is fortified because it is plant-based.

Food amounts also put labels into perspective. The NIH table lists 2.6 micrograms in a 3-ounce serving of cooked Atlantic salmon, 2.5 micrograms in the same serving of canned light tuna, 2.4 micrograms in 3 ounces of lean ground beef, 1.3 micrograms in a cup of 2% milk, and 0.5 micrograms in one cooked egg. Those are US reference values rather than a personalised meal prescription, but they show why a mixed diet can provide B12 without a separate tablet.

The same table makes a second point. A quarter cup of some fortified nutritional yeasts can contain 8.3 to 24 micrograms, while a serving of fortified breakfast cereal can contain 0.6 micrograms. Fortified products are not interchangeable. The brand, portion and label matter. People who use fortified foods as their main B12 source should check them periodically because recipes and fortification practices can change.

A food-first approach is not a demand that every person eat animal foods. It is a prompt to make the B12 source explicit. Someone eating animal foods regularly may meet their need through food. A person following a vegan pattern needs a dependable fortified-food and/or supplement plan. Healthdirect notes that fortified plant milks, some fortified meat substitutes and some breakfast cereals can be reliable vegan sources, provided the label confirms the added B12.

Absorption has more steps than most labels show

B12 from food is attached to protein. Stomach acid and digestive enzymes help release it, after which it first binds to haptocorrin, a B12-binding protein in saliva and the stomach. In the small intestine, digestive enzymes release B12 again. It then binds to intrinsic factor, a protein made by stomach parietal cells. The intrinsic-factor complex is absorbed in the far end of the small intestine, the ileum. B12 in a supplement or fortified food is already free from food protein, but intrinsic factor remains relevant to the main absorption pathway.

This pathway explains why diet is not the only issue. A person may consume B12-rich food and still have trouble absorbing it. Pernicious anaemia is an autoimmune condition in which the stomach cannot make enough intrinsic factor. Coeliac disease, Crohn disease, stomach or small-intestine surgery, and conditions affecting the stomach can also alter absorption. Older adults may have reduced stomach acid that makes it harder to release food-bound B12.

The body does keep a reserve. NIH estimates body stores at roughly 1 to 5 milligrams, around 1,000 to 2,000 times a typical day’s intake. Symptoms can therefore take years to appear after intake or absorption drops. That long timeline is another reason a recent change in diet does not automatically explain a low result, and why a long-standing problem can be missed until symptoms or blood changes appear.

Absorption also helps make sense of fortified foods. They provide free B12 rather than B12 trapped in a food-protein matrix. This does not mean they solve every absorption problem. It means that the route from label to bloodstream is different, and the cause of low status still determines whether ordinary oral intake is enough.

“Vitamin B12 testing is recommended for individuals with clinical signs and symptoms suggestive of B12 deficiency, and when there is reasonable clinical suspicion of deficiency due to risk factors.” — Australian Prescriber, February 2026

The quote matters because it shifts the question. If absorption is the concern, choosing a different flavoured lozenge may not address the cause. Testing and treatment should be tied to the individual situation.

Form matters less than marketing suggests. Common supplement forms include cyanocobalamin, methylcobalamin, adenosylcobalamin and hydroxycobalamin. Methylcobalamin and adenosylcobalamin are active forms used directly in metabolism; cyanocobalamin and hydroxycobalamin are converted in the body before use. Labels often imply that “methyl” automatically means better. The NIH consumer fact sheet says research has not shown that one supplemental form is better than another, and its health-professional fact sheet adds that there is no evidence supplement absorption rates vary by form. Claims about a form being uniquely absorbed, naturally energising or universally preferable need stronger evidence than a coloured label.

Sublingual tablets and sprays are another common sales angle. “Under the tongue” sounds as if it bypasses digestion entirely. Available evidence has not established clearly better efficacy for sublingual B12 compared with ordinary oral forms; a 2024 meta-analysis cited by Australian Prescriber found sublingual and oral supplementation appear about as effective as intramuscular injections at improving B12 status, though more high-quality trials are needed to confirm dosing strategies. For someone with a diagnosed absorption problem, route and dose should be chosen with clinical guidance, not from a marketing claim about a delivery format.

Who should pay closer attention

Risk is not a diagnosis. It is a reason to review intake, health history and, where appropriate, discuss testing with a clinician. Healthdirect and Australian Prescriber identify several groups worth considering.

• People who follow vegan diets, and some vegetarians with limited intake of animal foods, may not get enough naturally occurring B12.
• Older adults can have lower stomach acid or conditions affecting absorption.
• People with pernicious anaemia, coeliac disease, Crohn disease or other stomach and small-intestine disorders may absorb less B12.
• People who have had bariatric surgery, gastric surgery or ileal surgery may need a tailored plan.
• Long-term use of metformin, proton-pump inhibitors or H2-receptor blockers can be relevant to B12 status.
• Babies of people with low B12 status, particularly where a vegan diet is involved, need clinical attention rather than an improvised household supplement plan.

Being vegetarian or vegan does not automatically mean deficient. Equally, eating meat does not rule it out. A reliable source, regular intake and the ability to absorb it all matter. This is why broad claims that one diet or one capsule works for everyone are poor guidance.

Symptoms are clues, not proof

Fatigue, weakness, numbness or tingling in hands and feet, pale skin, balance trouble, memory changes and a sore tongue can occur with B12 deficiency. They can also occur with other conditions. Healthdirect lists fatigue, anaemia, numbness or tingling, memory problems and balance difficulties among common features of B12 deficiency.

Neurological signs deserve timely clinical assessment because B12-related nerve effects can occur even without anaemia, and delayed treatment may leave lasting harm. New or worsening weakness, numbness, trouble walking, confusion, severe shortness of breath or fainting should not be managed by changing supplements at home.

A symptom checklist cannot diagnose B12 deficiency. Pathlab’s New Zealand guidance says routine screening is not indicated and notes that there is no evidence supporting B12 testing as a first-line investigation for fatigue or dizziness alone. That is not a reason to dismiss symptoms. It is a reason to bring the full picture to a clinician: symptoms, diet, medicines, medical history and any prior results.

Timing complicates self-assessment. Because B12 stores can last for years, a person may not notice a clear symptom immediately after intake falls. The reverse is also true: long-standing tiredness does not reveal its cause simply because a B12 product is available. In people with confirmed deficiency, symptom improvement after treatment can take different lengths of time. Australian Prescriber reports that neurological symptoms may improve gradually over 6 to 12 weeks, while blood-count recovery follows a different timeline. Individual follow-up belongs with the treating clinician.

There is also a safety issue in assuming all nerve symptoms are nutritional. Tingling, weakness and balance changes have many possible causes, some requiring prompt care. A supplement can be part of a treatment plan, but it is not a diagnostic test.

A blood result needs context

Total serum B12 is commonly the first test when a clinician suspects deficiency. It measures B12 attached to its transport proteins, including both active and inactive fractions. Australian Prescriber describes active B12, also called holotranscobalamin, as the fraction bound to transcobalamin and available to cells. It may be considered when total B12 is indeterminate or in pregnancy.

Methylmalonic acid and homocysteine can help in some uncertain cases, but neither is a stand-alone answer. Methylmalonic acid may rise with kidney impairment; homocysteine can be affected by folate and B6 status, kidney disease and other factors. Laboratories use their own methods and reference ranges, so an internet cutoff should never override the result interpretation supplied with the test.

Australian Prescriber sets out approximate cutoffs used in practice: a total B12 result under about 133 pmol/L is treated as deficiency likely, a result between roughly 133 and 258 pmol/L as indeterminate, and a result above about 258 pmol/L as deficiency unlikely. Active B12 uses different cutoffs, with results under about 25 pmol/L treated as deficiency likely. These numbers illustrate why laboratories issue an interpretation alongside the raw figure rather than leaving patients to compare it against a number found online. A result that looks "low normal" against one cutoff can sit comfortably inside the normal range on another test type, and pregnancy, inflammation, liver disease and certain blood disorders can push total B12 in either direction without necessarily reflecting true tissue status.

Testing intervals matter too. Pathlab’s New Zealand guidance suggests retesting intervals of at least six months when B12 testing is clinically indicated, and Australian Prescriber notes that repeat testing is not usually needed within 12 months of a normal result unless a patient’s clinical status changes. Ordering a private test every few weeks to “check progress” of a supplement is rarely useful and adds cost without changing the underlying management plan.

The practical rule is simple: do not self-diagnose from one number, and do not use a high supplement dose to make a confusing result disappear. A clinician can decide whether the result fits the symptoms and whether the underlying cause needs investigation.

Cancer and heart disease claims outrun the evidence

Some marketing implies that more B12 protects the heart or reduces cancer risk. The evidence does not support a blanket claim in either direction.

On cardiovascular disease, B12 and other B vitamins lower blood homocysteine, and elevated homocysteine has been linked with cardiovascular risk in observational data. But NIH’s health-professional fact sheet reports that a Cochrane review of 15 studies covering more than 71,000 participants found that B12 supplementation, alone or with other B vitamins, does not prevent heart attacks or reduce death rates in people at risk of or living with cardiovascular disease. An extended follow-up of the B-PROOF trial, which combined 400 micrograms folic acid with 500 micrograms B12 daily, likewise found no effect on cardiovascular disease risk after a median of 54 months. Lower homocysteine on a lab report does not automatically translate into fewer heart attacks.

Cancer evidence is mixed and, in places, contradictory. Some observational studies associate higher B12 blood levels with increased cancer risk or worse survival after a cancer diagnosis; other observational data associate lower B12 with a higher risk of specific cancers such as gastric or colorectal cancer. A meta-analysis of 18 randomised trials with more than 74,000 participants found that B-vitamin supplements containing 20 to 2,000 micrograms per day of B12 had little or no effect on cancer incidence, cancer deaths or all-cause mortality. NIH’s own conclusion is direct: more evidence is needed to clarify whether high or low B12 intakes influence cancer risk. That uncertainty is a reason for caution on both sides, not a green light for high-dose “prevention” claims.

Dementia and cognitive function research follows a similar pattern. Observational studies link low B12 or elevated homocysteine with cognitive decline, but randomised trials have generally not shown that B12 supplementation, alone or combined with folic acid or B6, improves cognitive function in older adults with or without dementia. A supplement is not a substitute for a cognitive assessment when memory or thinking changes appear.

How to read a B12 supplement label

Start with the serving size. A panel may list one tablet, two gummies or one spray as a serving. Then check the actual B12 amount in micrograms and whether the product also contains folic acid, vitamin B6, iron or other ingredients. A B-complex can change more than one nutrient at once, which matters if you are already using a multivitamin.

Use this five-point check before buying:

1. Find the amount per daily serving, not just the number printed on the front.
2. Identify the B12 form, but do not assume methylcobalamin is automatically superior.
3. Check every active ingredient, especially in B-complex products.
4. Compare the product with your existing multivitamin, fortified foods and clinician’s advice to avoid needless duplication.
5. Treat disease-treatment or guaranteed-energy language cautiously. In New Zealand, dietary supplements cannot have a stated or implied therapeutic purpose.

Medsafe says dietary supplements are regulated under the Dietary Supplements Regulations 1985 within the Food Act 2014 framework, which Medsafe administers alongside the Ministry for Primary Industries. The rules include labelling and maximum permitted daily doses for some vitamins and minerals. There is no pre-approval process; the sponsor, meaning the business legally responsible for placing the product on the market, is responsible for product quality, safety and legal compliance. A product being on a shelf is not proof that it has been assessed by Medsafe as a medicine.

That regulatory gap matters for B12 specifically because high-dose B12 injections and nasal preparations sit in a different category from oral supplements. Injectable B12 in New Zealand is a prescription medicine, administered by or under the direction of a health professional, precisely because parenteral treatment is reserved for confirmed deficiency with a defined cause. A dietary supplement sold over the counter, by contrast, cannot legally carry a therapeutic claim such as treating anaemia or reversing nerve damage, even if the ingredient itself, B12, has a genuine therapeutic use in the right clinical context. If a product markets itself as treating a named condition, that claim itself is a signal to look more closely at whether it should be regulated as a medicine rather than sold as a general food supplement.

Treatment depends on the cause

A confirmed deficiency is not a one-size-fits-all supplement routine. Treatment depends on severity and cause. Dietary insufficiency may be managed with oral B12 under clinical guidance. Significant malabsorption, pernicious anaemia, severe symptoms or certain post-surgery situations can require injections or a specific long-term plan.

Australian Prescriber sets out how those choices are typically made. For irreversible malabsorption, such as pernicious anaemia, total gastrectomy or terminal ileum resection, the recommended approach is intramuscular hydroxocobalamin on alternate days for one to two weeks, then weekly for four to eight weeks as a loading regimen, followed by an injection roughly every three months for life. The guidance is direct that the oral route is considered unreliable for this group even at high doses, which is why an over-the-counter tablet cannot substitute for injectable treatment once this cause is confirmed. For drug-induced deficiency, for example from long-term metformin, proton pump inhibitors or H2-receptor blockers, oral cyanocobalamin at 1 milligram daily or intramuscular treatment may be used, generally continued only until the causative drug stops and the deficiency is corrected, then reassessed three to six months later. For straightforward dietary insufficiency, such as a vegan or vegetarian diet without malabsorption, high-dose oral cyanocobalamin at 1 milligram daily, without a loading phase, is usually preferred, and Australian Prescriber notes it tends to be more cost effective and preferred by patients, with intramuscular treatment reserved for poor adherence or access barriers.

Australian Prescriber notes that confirmed deficiency requires supplementation, with formulation, duration and dose guided by cause, severity and preference. It describes intramuscular treatment as important for severe symptomatic deficiency and irreversible malabsorption, including cases with neurological involvement such as subacute combined degeneration of the spinal cord, where rapid parenteral therapy is used to prevent damage that may not be fully reversible even after correction. Those are medical decisions. Do not substitute a wellness product for prescribed treatment, and do not stop prescribed injections because an oral product looks stronger on paper.

Folate deserves a brief warning. Folate and B12 both affect red blood cell production. Taking folic acid can improve some blood changes while a B12-related neurological problem continues untreated underneath. That is one reason unexplained anaemia or neurological symptoms should be assessed properly rather than treated with a random B-complex bought to cover every possibility at once.

Vitamin B12 has a modest daily target and a complicated route into the body. That combination is exactly why labels can mislead: a very large number can sit beside a product that is unnecessary for one person and insufficiently targeted for another.

If you eat animal foods regularly and have no relevant symptoms or risk factors, an additional B12-only product may add little beyond what your diet already supplies. If you avoid animal foods, check that your fortified-food or supplement plan is dependable and confirm the actual micrograms on the label rather than assuming the product covers your needs. If you have numbness, balance change, unexplained anaemia, a relevant gut condition, bariatric surgery, or long-term use of metformin or acid-suppressing medicines, talk with a clinician or pharmacist about whether testing makes sense before choosing a product on your own.

The best B12 purchase is not always the largest dose on the shelf. It is the one that matches a real, understood need, a clear plan for how long to take it, and a reason grounded in your own diet, medical history and, where relevant, a blood test rather than a marketing claim.

Sources: NIH Office of Dietary Supplements, Australian Prescriber, Healthdirect Australia, Pathlab New Zealand, Medsafe New Zealand, and Health New Zealand.

Sources

ods.od.nih.gov

ods.od.nih.gov

australianprescriber.tg.org.au

www.healthdirect.gov.au

www.pathlab.co.nz

www.medsafe.govt.nz

www.healthnz.govt.nz

This article is for general education and does not replace advice from a qualified healthcare professional.